Journal article
Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial
Abstract
BACKGROUND AND AIMS: FREEDOM, a cardiovascular outcome trial with a GLP-1 receptor agonist, testing a continuous subcutaneous infusion of exenatide (ITCA 650), recently reported its findings.
METHODS: We meta-analysed its results with eight prior GLP-1 receptor agonists trials.
Authors
Lee MMY; Kristensen SL; Gerstein HC; McMurray JJV; Sattar N
Journal
Diabetes & Metabolic Syndrome Clinical Research & Reviews, Vol. 16, No. 1,
Publisher
Elsevier
Publication Date
1 2022
DOI
10.1016/j.dsx.2021.102382
ISSN
1871-4021